Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 132 results:
[ Συντάκτης] Τίτλος Τύπος Έτος Φίλτρα: Συντάκτης is Polyzos, Stergios A [Clear All Filters]
Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach?.
Hepatology. 68(1), 389.
(2018). Diabetes mellitus: 100 years since the discovery of insulin..
Metabolism. 118, 154737.
(2021). Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease..
J Renin Angiotensin Aldosterone Syst. 12(4), 498-503.
(2011). Nonalcoholic fatty future disease..
Metabolism. 65(8), 1007-16.
(2016). Endocrine and metabolic disorders interplaying with non-alcoholic fatty liver disease..
Minerva Endocrinol. 42(2), 89-91.
(2017). Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment..
Hormones (Athens). 17(4), 573-579.
(2018). Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer..
Hormones (Athens).
(2022). Serum visfatin in nonalcoholic fatty liver disease..
Ann Hepatol. 13(1), 150-1.
(2013). Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort..
Horm Metab Res. 51(2), 134-140.
(2019). Alterations in serum thyroid-related constituents after thyroid fine-needle biopsy: a systematic review..
Thyroid. 20(3), 265-71.
(2010). Sarcopenia: still in relative definition-penia and severe treatment-penia..
Metabolism. 155717.
(2023). Helicobacter pylori infection, insulin resistance and nonalcoholic fatty liver disease..
Med Hypotheses. 82(6), 795.
(2014). Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis..
Ann Hepatol. 19(5), 579-580.
(2020). The potentially dual-faceted nature of fetuin-A in Helicobacter pylori infection and insulin resistance..
Clinics (Sao Paulo). 66(5), 911-2.
(2011). Novel Advances in the Association Between Helicobacter pylori Infection, Metabolic Syndrome, and Related Morbidity..
Helicobacter. 20(6), 405-9.
(2015). Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study..
Arq Gastroenterol. 51(3), 261-8.
(2014). Clinical vertebral fractures following denosumab discontinuation..
Endocrine. 54(1), 271-272.
(2016).
(2019). Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations..
Maturitas. 147, 19-25.
(2021). Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease..
J Clin Gastroenterol. 46(4), 272-84.
(2012). Irisin in metabolic diseases..
Endocrine. 59(2), 260-274.
(2018). Insulin resistance and therapy: cross-talk between phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways..
Med Hypotheses. 72(5), 610.
(2009). Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis..
Curr Med Chem.
(2023). Helicobacter pylori infection and serum adiponectin..
Helicobacter. 18(4), 321-2.
(2013). Off-label uses of denosumab in metabolic bone diseases..
Bone. 129, 115048.
(2019).